AbbVie today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab soravtansine-gynx) in women with folate receptor alpha ...
This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback